Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

作     者：Jaime Ceballos-Viro José M López-Picazo José L Pérez-Gracia Jesús J Sola Gregorio Aisa Ignacio Gil-Bazo 

作者机构：Department of OncologyClínica Universidad de NavarraPio XII 3631008 PamplonaSpain Department of PathologyClínica Universidad de NavarraPio XII 3631008 PamplonaSpain 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2009年第15卷第18期

页      面：2290-2292页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100214[医学-肿瘤学] 10[医学] 

主　　题：Fibrosing cholestatic hepatitis Immunosuppression Chemotherapy Lung cancer Hepatitis Bvirus Lamivudine 

摘      要：Fibrosing cholestatic hepatitis(FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver,renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic *** constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological ***,we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced *** is the first reported case in the literature of FCH after conventional chemotherapy for a solid *** addition to a detailed report of the case,a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.